📌 Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges 👉🏻 sciencedirect.com/science/articl… @ilanaschlam.bsky.social @loisher.bsky.social @oncoalert.bsky.social

Don't miss this recent review outlining practical treatment strategies and novel therapies in the PI3K/AKT/mTOR pathway in HR+/HER2- advanced #BreastCancer 🔓 pubmed.ncbi.nlm.nih.gov/39674130/ @antgiordanomd.bsky.social @drtimothyerick.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social

🔥Nature Medicine🆙 ✅Evaluating generalizability of oncology trial results to real-world pts using machine learning-based trial emulations 🎯Decision support/estimation of RW treatment benefit 👥Drs. Xavier Orcutt, Ravi B. Parikh et al. #LCSM @oncoalert.bsky.social #AI www.nature.com/articles/s41...

Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations - Nature Medicine

Machine-learning-based and population-level electronic health record data–based emulation of landmark phase 3 randomized controlled trials (RCTs) in oncology across a range of cancer and risk types sh...

nature.com

The BRIDGES study @JCO GO ❓ Management of IBC in low and middle income countries ✅ 112 responses from clinicians from 36 counties 🔑 1/3 of patients with non metastatic IBC are receiving TMT 🔑 provider education everywhere is key to improve patient outcomes ascopubs.org/doi/pdf/10.1...

RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor. 2nd line PFS >11 months with fulvestrant. Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores. Hoping this one moves forward! #SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social

🩸🧬Exciting update! LB-RECIST introduces a new era for evaluating tumor response using liquid biopsy addressing limits of imaging in solid tumors. A step toward precision oncology! @oncoalert.bsky.social @christianrolfo.bsky.social @viveksubbiah.bsky.social www.annalsofoncology.org/action/showP...

Wrapping up another fantastic #SABCS! Amazing, practice-changing data were presented. I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease! #SABCS24 @oncoalert.bsky.social

Dr. Turner presents #ZEST adj study of MRD in pts with HR + w/ BRCA & TNBC all comers w/ niraparib as intervention 147 had ctDNA+, only 40 randomized Rad recurrence assoc w/ ⬆️ ctDNA level RFI 5.4 -> 11.4 mo w/ niraparib #SABCS24 @sabcs.bsky.social @oncoalert.bsky.social

PRACTICE CHANGING findings from PATINA presented by Dr. Metzger from @dfcibreastonc.bsky.social - n=518 HR+/HER2+ mBC - all received THP followed by HP+ET +/- palbo - PFS was 29 vs 44 months with palbo - Tox consistent with prior studies

Great discussion of novel biomarkers and HER2-targeted TKIs by @ptarantinomd.bsky.social @dfcibreastonc.bsky.social

Stellar discussion by Dr Burstein on the important findings of EMBER-3 presented by Dr Jhaveri Some important clinical questions: ❓how to incorporate these findings in clinic - with the approval of inavo-? ❓are we ready for ADC post ADC? ❓how to sequence these agents?

#EMBER3 Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1 * note prior CDK not required #SABCS24 @sabcs.bsky.social @oncoalert.bsky.social

Outstanding spotlight poster discussion by Thomas Grinda from Gustave Roussy. Promising results with the 1L combination of chemo, IO and VEGF blockade for mTNBC. Will the inclusion of IO in the combo change the story of VEGF, previously thought not to improve long-term outcomes for breast cancer?

Practice change ALERT in the POST-CDK4/6 HR+, HER2- space.

NEJM.org@nejm.org · 2y ago

The selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs. 5.5 months with imlunestrant alone). Full EMBER-3 trial results: nej.md/4fZ74HX #MedSky #SABCS24

We're kicking off the first day of our LIVE coverage of #SABCS24 with expert insights from @ilanaschlam.bsky.social of @danafarber.bsky.social, who will be taking over the @OncLive X and Bluesky🦋 accounts to cover this evening's sessions! Be sure to tune in! @sabcs.bsky.social #bcsm #oncology

The ASCO virtual mentoring program (VMP) is now accepting applications; this is a great opportunity for trainees. This program was career-changing for me. Consider applying! @stolaney1.bsky.social @dfcibreastonc.bsky.social asco.smapply.org/prog/2025-26...

I created a SABCS Breast Thought Leader Starter Pack for anyone new to @bsky.app and following @sabcs.bsky.social Will try to add all thought leaders as I go! go.bsky.app/MkqBYa7

Here’s the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (December 2nd-8th, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

Check out this recent review on the role of #AntibodyDrugConjugates in the treatment of patients with #BreastCancerBrainMetastases. pubmed.ncbi.nlm.nih.gov/39529890/ #StaceyPan @drsarahsammons.bsky.social @nlinmd.bsky.social @stolaney1.bsky.social @ilanaschlam.bsky.social @ptarantinomd.bsky.social

Make sure to follow @dfcibreastonc.bsky.social for updates on the latest research efforts by DFCI BOC and for periodic research digest with recent news in breast oncology! @stolaney1.bsky.social

Impact of cycle 1 irAEs on ICI outcomes: - 683pts from SWOG DART trial - g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001 - g3+ irAEs = ⬇️OS HR  1.41 p= .025 - g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002 Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social academic.oup.com/jnci/advance...

First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors

AbstractBackground. Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluate

academic.oup.com

Looking forward to #SABCS24 - there is a lot of important research being presented, some to highlight: 🔑 Biomarker analysis of KN522 🔑 EMBER-3 🔑 MARGOT 🔑 SONIA 🔑 EUROPA 🔑 SOLTI VALENTINE 🔑 GeparDouze

Regular abstracts from #SABCS24 are out! 3407 pages of new breast cancer discoveries. Find them here: sabcs.org/Portals/0/Do...

Strong showing by #OhioState #BreastMedOnc for 100 top oncoinfluencers @stoverlab.bsky.social @quirogad.bsky.social Dr Arya Roy. Honored to be included and looking forward to this list for 🦋 next year! oncodaily.com/positive/bre...

Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024 - OncoDaily

Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024 / 2-PREVENT Breast Cancer TCE, ABCD After Breast Cancer Diagnosis,

oncodaily.com

Findings highlight ‘critical importance’ of infectious complications after CAR-T - read HemeOncToday interview with Kai Rejeski and me #medsky #CARTcells www.healio.com/news/hematol...

Findings highlight ‘critical importance’ of infectious complications after CAR-T

Infections are the primary cause of nonrelapse mortality among individuals who undergo chimeric antigen receptor T-cell therapy, according to study results.Unique CAR-T-specific side effects &mdash; s...

healio.com

Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!

Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!